<DOC>
	<DOC>NCT01175135</DOC>
	<brief_summary>This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.</brief_summary>
	<brief_title>An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis of schizophrenia with acute exacerbation of illness The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation. Subjects with evidence or history of clinically significant uncontrolled medical illness Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder. Subjects who meet Diagnostic and Statistical ManualIV (DSMIV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSMIV defined substance abuse within 3 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>acute exacerbation</keyword>
	<keyword>inpatient</keyword>
</DOC>